Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.52 |
| ▸ | KDR | P35968 | 7/20 | 0.52 |
| ▸ | BRAF | P15056 | 6/20 | 0.52 |
| ▸ | RAF1 | P04049 | 3/20 | 0.52 |
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.52 |
| ▸ | FLT1 | P17948 | 2/20 | 0.52 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.52 |
| ▸ | TTK | P33981 | 2/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.52 |
| ▸ | CLK1 | P49759 | 2/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.52 |
| ▸ | CDK17 | Q00537 | 2/20 | 0.52 |
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12079338 | 0.94 | MAPK14 (0.51) | MAPK14KDRBRAFRAF1ABL1 | |
| Hydrochloric Acid SCHEMBL2031636 | 0.94 | MAPK14 (0.51) | MAPK14KDRBRAFRAF1ABL1 | |
| SCHEMBL1660418 | 0.81 | MAPK14 (0.54) | MAPK14KDRBRAFRAF1ABL1 | |
| SCHEMBL1660260 | 0.80 | MAPK14 (0.60) | MAPK14KDRBRAFRAF1ABL1 | |
| SCHEMBL2031987 | 0.78 | RAF1 (0.61) | MAPK14KDRBRAFRAF1ABL1 | |
| SCHEMBL1662382 | 0.77 | DDR2 (0.51) | MAPK14KDRBRAFRAF1ABL1 | |
| SCHEMBL30681113 | 0.77 | ABL1 (0.70) | MAPK14KDRBRAFRAF1ABL1 | |
| SCHEMBL2031878 | 0.77 | ABL1 (0.70) | MAPK14KDRBRAFRAF1ABL1 | |
| Hydrochloric Acid SCHEMBL2027993 | 0.76 | ABL1 (0.69) | MAPK14KDRBRAFRAF1ABL1 | |
| SCHEMBL2029025 | 0.76 | ABL1 (0.86) | MAPK14KDRBRAFRAF1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013036232-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2073811-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046003-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | MAPK14 323/4885KDR 1898/4885BRAF 5/4885 |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | MAPK14 354/4885KDR 2394/4885BRAF 115/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | MAPK14 354/4885KDR 2394/4885BRAF 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.